Company: BNBX
Filing Date: 2025-11-04
Form Type: 424B5
Source: 0001104659-25-105958
Chunk: 50

Company: BNB PLUS CORP.
Filing Date: 2025-11-04
Form: 424B5
Chunk 50
---
”); and (iii) the manufacture and detection
of DNA for industrial supply chain security services (“DNA Tagging and Security Products and Services”).

Our current growth strategy
is to primarily focus our resources on the further development, commercialization, and customer adoption of our Therapeutic DNA Production
Services, including the expansion of our contract development and manufacturing operation (“CDMO”) for the PCR-based manufacture
of synthetic DNA for use in the manufacturing of nucleic acid-based therapies and the development of our own DNA-based product candidates
in veterinary health.

Corporate History

We are a Delaware corporation,
which was initially formed in 1983 under the laws of the State of Florida as Datalink Systems, Inc. In 1998, we reincorporated in
the State of Nevada, and in 2002, we changed our name to our current name, Applied DNA Sciences, Inc. On December 17, 2008,
we reincorporated from the State of Nevada to the State of Delaware.

Our corporate headquarters
are located at the Long Island High Technology Incubator at Stony Brook University in Stony Brook, New York, where we have established
laboratories for the manufacture and detection of DNA to support our various business units. In addition, this location also houses our
New York State Department of Health (“NYSDOH”) Clinical Laboratory Evaluation Program (“CLEP”)-permitted, Clinical
Laboratory Improvement Amendments (“CLIA”)-certified clinical laboratory where we perform MDx Testing Services. The mailing
address of our corporate headquarters is 50 Health Sciences Drive, Stony Brook, New York 11790, and our telephone number is (631) 240-8800.

<div align='center'>2

RISK FACTORS</div>

Investing in our securities involves a high degree of risk. Prior to
making a decision about investing in our securities, you should carefully consider and evaluate the specific factors discussed under the
heading “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2022 filed on December 14, 2022, with the SEC, as amended, and any updates described in subsequent Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and
Periodic Reports on Form 8-K, all of which are incorporated herein by reference, and may be amended, supplemented or superseded from time
to time by other reports we file with the SEC in the future. The risks and